132 related articles for article (PubMed ID: 38075128)
1. Retracted: FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma.
And Biomechanics AB
Appl Bionics Biomech; 2023; 2023():9798134. PubMed ID: 38075128
[TBL] [Abstract][Full Text] [Related]
2. FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma.
Wu S; Liang Y; Zang Q; Xing Z; Yin P; Sun R; Dai B
Appl Bionics Biomech; 2022; 2022():5160748. PubMed ID: 35607429
[TBL] [Abstract][Full Text] [Related]
3. Retracted: miR-100-5p Is a Novel Biomarker That Suppresses the Proliferation, Migration, and Invasion in Skin Cutaneous Melanoma.
International SC
Stem Cells Int; 2023; 2023():9861375. PubMed ID: 38152723
[TBL] [Abstract][Full Text] [Related]
4. Retracted: Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer.
International BR
Biomed Res Int; 2023; 2023():9870382. PubMed ID: 37388379
[TBL] [Abstract][Full Text] [Related]
5. Retracted: Melanoma Molecular Subtypes and Development of Prognostic and Immunotherapy-Related Genetic Characteristics by Ferroptosis Gene Analysis.
Methods In Medicine CAM
Comput Math Methods Med; 2023; 2023():9756912. PubMed ID: 38124903
[TBL] [Abstract][Full Text] [Related]
6.
Huang Y; Lin A; Gu T; Hou S; Yao J; Luo P; Zhang J
Immunotherapy; 2023 Oct; 15(15):1275-1291. PubMed ID: 37584225
[No Abstract] [Full Text] [Related]
7. Retracted: Automated Diagnosis and Localization of Melanoma from Skin Histopathology Slides Using Deep Learning: A Multicenter Study.
Healthcare Engineering JO
J Healthc Eng; 2023; 2023():9847323. PubMed ID: 38094829
[TBL] [Abstract][Full Text] [Related]
8. Retracted: Value of a Signature of Immune-Related Genes in Predicting the Prognosis of Melanoma and Its Responses to Immune Checkpoint Blocker Therapies.
Methods In Medicine CAM
Comput Math Methods Med; 2023; 2023():9781954. PubMed ID: 37416155
[TBL] [Abstract][Full Text] [Related]
9. SMG7-AS1 as a prognostic biomarker and predictor of immunotherapy responses for skin cutaneous melanoma.
Xu X; Ju Y; Zhao X; Yang P; Zhu F; Fang B
Genomics; 2023 May; 115(3):110614. PubMed ID: 36931476
[TBL] [Abstract][Full Text] [Related]
10. Retracted: CDC20 May Serve as a Potential Biomarker-Based Risk Score System in Predicting the Prognosis of Patients with Hepatocellular Carcinoma.
Longevity OMAC
Oxid Med Cell Longev; 2023; 2023():9806284. PubMed ID: 37565158
[TBL] [Abstract][Full Text] [Related]
11. Retracted: A Novel Biomarker, FKBP10, for Poor Prognosis Prediction in Patients with Clear Cell Renal Cell Carcinoma.
And Alternative Medicine EC
Evid Based Complement Alternat Med; 2023; 2023():9780837. PubMed ID: 37829649
[TBL] [Abstract][Full Text] [Related]
12. Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy.
Karlsson MJ; Costa Svedman F; Tebani A; Kotol D; Höiom V; Fagerberg L; Edfors F; Uhlén M; Egyhazi Brage S; Maddalo G
Cancer Res; 2021 May; 81(9):2545-2555. PubMed ID: 33574091
[TBL] [Abstract][Full Text] [Related]
13. Screening and identification of potential prognostic biomarkers in metastatic skin cutaneous melanoma by bioinformatics analysis.
Sheng Z; Han W; Huang B; Shen G
J Cell Mol Med; 2020 Oct; 24(19):11613-11618. PubMed ID: 32869947
[TBL] [Abstract][Full Text] [Related]
14. Retracted: Considering Computational Mathematics IGHG3 as Malignant Melanoma Is Associated with Immune Infiltration of Malignant Melanoma.
International BR
Biomed Res Int; 2024; 2024():9829716. PubMed ID: 38550022
[TBL] [Abstract][Full Text] [Related]
15. Retracted: Prognostic Value of Lactate Dehydrogenase, Melanoma Inhibitory Protein, and S-100B Protein in Patients with Malignant Melanoma.
And Alternative Medicine EC
Evid Based Complement Alternat Med; 2023; 2023():9846920. PubMed ID: 37829638
[TBL] [Abstract][Full Text] [Related]
16. The immune system--a hidden treasure for biomarker discovery in cutaneous melanoma.
Neagu M
Adv Clin Chem; 2012; 58():89-140. PubMed ID: 22950344
[TBL] [Abstract][Full Text] [Related]
17. Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma.
Xue L; Wu P; Zhao X; Jin X; Wang J; Shi Y; Yang X; She Y; Li Y; Li C
Int J Gen Med; 2021; 14():6463-6475. PubMed ID: 34675614
[TBL] [Abstract][Full Text] [Related]
18. Retracted: NOD1 and NOD2 Are Potential Therapeutic Targets for Cancer Immunotherapy.
Intelligence And Neuroscience C
Comput Intell Neurosci; 2023; 2023():9847813. PubMed ID: 37600249
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
